Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MEDTRONIC PLC

(MDT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Medtronic : Hugo Robotic-Assisted Surgery System Receives European CE Mark Approval

10/12/2021 | 06:42am EST

DUBLIN - Medtronic plc (NYSE:MDT), the global leader in medical technology, announced it has received CE (Conformite Europeenne) Mark for the Hugo robotic-assisted surgery (RAS) system, authorizing the sale of the system in Europe. CE Mark approval is for urologic and gynecologic procedures, which make up about half of all robotic procedures performed today.

'This day has been a long time coming, not just for Medtronic, but for the surgeons and hospital leaders who have partnered with us on this journey to bring the benefits of robotic-assisted surgery to more patients around the world. We know our solution is more meaningful because of their insights,' said Megan Rosengarten, president of the Surgical Robotics business, which is part of the Medical Surgical Portfolio at Medtronic. 'With the Hugo RAS system in our European customers' hands and our dedicated team by their side, together we will redefine what is possible in robotic-assisted surgery.'

The Hugo RAS system was designed to address the historic cost and utilization barriers that have stifled robotic surgery adoption for two decades. Globally, about 3% of surgeries are performed robotically,1 despite offering patients the benefits of minimally invasive surgery - fewer complications, shorter hospital stays, and faster return to normal activities.2-4,(+) In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery.1 The remainder are traditional minimally invasive surgery.1

'Robotics and artificial intelligence are the undeniable future of healthcare, with incredible potential to not only advance patient care, but increase access to these benefits,' said Rob ten Hoedt, executive vice president and president of the Europe, Middle East, and Africa (EMEA) region at Medtronic. 'The Hugo RAS system builds on our leadership in minimally invasive surgery, and we're thrilled to provide hospitals across Europe a robotic-assisted surgery system that is thoughtfully designed to meet their needs today and tomorrow. We've had strong interest from leading surgical centers across Europe and expect to move quickly with multiple installations in several countries.'

These hospitals will be the first in Europe to join Medtronic's Partners in Possibility Program, a group of pioneering institutions that will be among the first in the world to use the Hugo RAS system and participate in the global patient registry. Clinicians from these hospitals will participate in hands-on training at Medtronic Surgical Robotics Experience Centers, including two flagship sites operated in partnership with the ORSI Academy in Ghent, Belgium, and IRCAD in Strasbourg, France.

CE Mark approval comes on the heels of major milestones in the Hugo RAS system global launch, including the first urological and gynecological procedures, which took place in Latin America and India and marked the start of the Hugo RAS system global patient registry. A modular, multi-quadrant platform designed for a broad range of surgical procedures, the Hugo RAS system combines wristed instruments, 3D visualization, and a cloud-based surgical video capture option in Touch Surgery Enterprise with dedicated support teams specializing in robotics program optimization, service, and training.

The Hugo RAS system is commercially available in certain geographies. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the EU, the Hugo RAS system is CE marked. In the U.S., the Hugo RAS system is an investigational device not for sale. Touch Surgery Enterprise is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.

For more information, visit medtronic.com/hugo(opens new window).

About Medtronic

Medtronic plc (www.medtronic.com(opens new window)), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Compared to open surgery.

1. Based on internal estimates and Medtronic report, FY20 market model: procedural volume data.

2. Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015 Sep;24(9):40-48.

3. Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127-1135.

4. Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innov. 2005;12(3):261-287.

Contact:

Gary Jeanfaivre

Public Relations

T: +1-203-833-2104

Ryan Weispfenning

Investor Relations

T: +1-763-505-4626

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about MEDTRONIC PLC
12/02MEDTRONIC PLC Management's Discussion and Analysis of Financial Condition and Results ..
AQ
12/01Cloud DX selected by Medtronic for national collaboration
AQ
11/30Medtronic receives Health Canada licence for GI Genius™ intelligent endoscopy mod..
AQ
11/28Vincent Medical Strikes Product Distribution Deal with NYSE-listed Medtronic; Shares Ra..
MT
11/24JPMorgan Adjusts Medtronic's Price Target to $130 from $148, Keeps Overweight Rating
MT
11/24Bernstein Adjusts Medtronic's Price Target to $143 from $148, Keeps Outperform Rating
MT
11/24Stifel Adjusts Medtronic's Price Target to $140 from $145, Keeps Buy Rating
MT
11/24Raymond James Adjusts Medtronic's Price Target to $127 from $142, Keeps Outperform Rati..
MT
11/24Truist Securities Adjusts Medtronic's Price Target to $142 from $148, Keeps Buy Rating
MT
11/24Wells Fargo Adjusts Medtronic's Price Target to $137 From $144, Reiterates Overweight R..
MT
More news
Analyst Recommendations on MEDTRONIC PLC
More recommendations
Financials (USD)
Sales 2022 32 396 M - -
Net income 2022 5 378 M - -
Net Debt 2022 22 296 M - -
P/E ratio 2022 27,4x
Yield 2022 2,35%
Capitalization 144 B 144 B -
EV / Sales 2022 5,12x
EV / Sales 2023 4,73x
Nbr of Employees 90 000
Free-Float 99,8%
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 106,87 $
Average target price 141,32 $
Spread / Average Target 32,2%
EPS Revisions
Managers and Directors
Geoffrey Straub Martha Chairman & Chief Executive Officer
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Laura Mauri Chief Clinical & Regulatory Officer, Senior VP
Richard E. Kuntz Chief Medical & Scientific Officer, Senior VP
Gregory L. Smith Executive VP-Global Operations & Supply Chain
Sector and Competitors
1st jan.Capi. (M$)
MEDTRONIC PLC-8.77%143 693
ABBOTT LABORATORIES18.98%227 013
BECTON, DICKINSON AND COMPANY-3.42%68 717
HOYA CORPORATION28.35%57 923
DEXCOM, INC.51.53%54 298
SARTORIUS STEDIM BIOTECH65.52%50 244